Amine Addition Salt Of Organic Phosphorus Containing Acid Patents (Class 514/76)
  • Patent number: 9901616
    Abstract: Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core. If the nanoparticle includes therapeutic agents, the agents are preferably released from the core at a desired rate. The core may be biodegradable and may release the agents as the core is degraded or eroded. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components, which interactions will target the nanoparticles to the appropriate cells, such as apoptotic cells; organelles, such as mitochondria; or the like. The targeting moieties may be tethered to the core or components that interact with the core.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 27, 2018
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Shanta Dhar, Sean Marrache
  • Patent number: 9125803
    Abstract: Disclosed are pharmaceutical products for providing pulses of at least one pharmaceutically active ingredient from a patient's stomach, or from a subsequent gastrointestinal site proximal thereto, for absorption thereof at a site(s) more distal in the gastrointestinal tract than the patient's stomach, or than the subsequent gastrointestinal site proximal thereto. The product comprises first, second, and third pharmaceutical dosage forms, each of which comprises at least one pharmaceutically active agent and a pharmaceutically acceptable carrier. The product is formulated such that at least two of the first, second, and third pharmaceutical dosage forms further comprise means for providing temporary gastric-retention of the at least two of the first, second, and third pharmaceutical dosage forms within the patient's stomach, or at the subsequent gastrointestinal site proximal thereto.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: September 8, 2015
    Assignee: Shionogi Inc.
    Inventors: Henry H. Flanner, Donald Treacy, Sanna Tolle-Sander, Scott Ibrahim, Marcus Schestopol, Beth A. Burnside
  • Publication number: 20140357597
    Abstract: The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Inventors: Thomas SEITZ, Ulrike Wachendorff-Neumann, Peter Dahmen
  • Patent number: 8889625
    Abstract: The present invention provides methods, compositions, and systems for treating a subject at risk for, with, or suspected of having, myocardial ischemia using hepatocyte secretory factors (e.g., AGP2, BMPER, FGF21, NRG4, and/or TFF3) or using factors that promote liver cell migration to ischemic myocardial tissue (e.g., IL-6 and/or MMP-2).
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: November 18, 2014
    Assignee: Northwestern University
    Inventor: Shu Q. Liu
  • Patent number: 8889657
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 18, 2014
    Assignee: Mallinckrodt LLC
    Inventor: Thomas E. Rogers
  • Patent number: 8835409
    Abstract: 3-Alkenyl-6-halo-4-aminopicolinic acids and their derivatives are potent herbicides demonstrating a broad spectrum of weed control.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: September 16, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Joseph D. Eckelbarger, Jeffrey B. Epp, Paul R. Schmitzer, Thomas L. Siddall
  • Patent number: 8795659
    Abstract: The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: August 5, 2014
    Assignee: Dekk-Tec, Inc.
    Inventor: Lee R. Morgan
  • Patent number: 8778838
    Abstract: The present invention relates to aqueous concentrate formulations for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its anhydrate; N-(phosphonomethyl)glycine in the form of its free acid, in the form of the ammonium salt or a substituted ammonium salt or a mixture thereof; at least two different non-ionic surfactants with at least one of them comprising an ethylene oxide polymer moiety or an ethylene oxide/C3-C4-alkylene oxide block copolymer moiety, and water; wherein the pH-value of the formulation is below 6.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: July 15, 2014
    Assignee: BASF SE
    Inventors: Michael Krapp, Wolfgang Gregori, Sven Adam, Klaus Kolb, Juergen Jakob, Bernd Sievernich, Joerg Steuerwald, Steven Bowe, Joseph Zawierucha, Rex Liebl
  • Publication number: 20140134270
    Abstract: A composition contains an agricultural pesticide and an incompletely hydrated water soluble polymer suspended in a liquid medium.
    Type: Application
    Filed: January 21, 2014
    Publication date: May 15, 2014
    Applicant: Rhodia Operations
    Inventors: Dan WU, Krish Murthy SHANMUGA, Rajesh GOYAL, Valerio BRAMATI
  • Patent number: 8716363
    Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Globus Medical, Inc.
    Inventor: Vipin Kunjachan
  • Patent number: 8703744
    Abstract: Provided are methods of reducing cellular cholesterol levels using lipid particles that are capable of cellular entry. Such lipid particles may be used for treating or preventing a disease or condition that is caused by or associated with an increased cellular cholesterol level and for treating or preventing a disease or condition, that is caused by or associated with a virus, that relies on cellular cholesterol for its replication.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: April 22, 2014
    Assignee: The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Stephanie Pollock, Raymond Dwek, Nicole Zitzmann
  • Patent number: 8663606
    Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 4, 2014
    Assignee: Medigene AG
    Inventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
  • Patent number: 8637688
    Abstract: The present invention relates to pharmaceutical dosage forms for topical administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: January 28, 2014
    Inventors: Julia Diederichs, Wolfgang Richter, Lutz Weber
  • Patent number: 8609142
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 17, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Patent number: 8604007
    Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 10, 2013
    Assignee: Ziopharm Oncology, Inc.
    Inventors: John C. Amedio, Jr., Barbara P. Wallner, Philip B. Komarnitsky
  • Patent number: 8486916
    Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: July 16, 2013
    Assignee: Megmilk Snow Brand Co., Ltd.
    Inventors: Ken Kato, Susumu Miura, Leo Tanaka, Hiroshi Ueno, Noriko Ueda, Yuko Haruta, Toshimitsu Yoshioka
  • Publication number: 20130172293
    Abstract: An objective of the present invention is to provide a novel method with an effect of alleviating central nervous system inflammation. The present invention provides a drug against central nervous system inflammation containing a plasmalogen. More preferably, the present invention provides a drug against central nervous system inflammation containing a plasmalogen extracted from a biological tissue (preferably an avian tissue) that mainly contains an ethanolamine plasmalogen and a choline plasmalogen.
    Type: Application
    Filed: September 22, 2011
    Publication date: July 4, 2013
    Applicants: FUJINO BRAIN RESEARCH CO.,LTD., UMEDA JIMUSHO LTD., MARUDAI FOOD CO., LTD.
    Inventors: Shirou Mawatari, Takehiko Fujino, Masataka Ifuku, Masaaki Sugiyama, Hidetaka Fuchu
  • Publication number: 20130149296
    Abstract: The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.
    Type: Application
    Filed: July 3, 2012
    Publication date: June 13, 2013
    Inventor: Lee R. MORGAN
  • Patent number: 8334408
    Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: December 18, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Patent number: 8324188
    Abstract: A method to determine the utility of small molecules as functional replacements (mimetics) for protein receptor ligands is described. The method uses cellular biological assays on a systematic array of compounds, comprising known protein receptor ligands and other biologically active molecules to determine if a proposed small molecule is a functional equivalent of a receptor ligand, having therapeutic utility as a pharmaceutically relevant and useful agent either alone or in combination with other molecules. Furthermore, the invention provides for a method for the treatment of cancer comprising administering a combination of ET-18-O-CH3 and an anti-cancer agent.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: December 4, 2012
    Inventors: Vladimir Khazak, Lutz Weber
  • Publication number: 20120258934
    Abstract: The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration, suitable for diabetics and not entailing gastrointestinal problems. The pharmaceutical composition of this invention comprises fosfomycin trometamol, glycine, and optionally other excipients as sucralose, silice dioxide, polyvinylpyrrolidone and flavour; and is substantially free from sugars and sugar alcohols as sucrose, fructose, glucose, xylitol, mannitol, sorbitol or mixtures thereof.
    Type: Application
    Filed: March 19, 2012
    Publication date: October 11, 2012
    Inventor: PICORNELL DARDER CARLOS
  • Publication number: 20120237651
    Abstract: A method of reducing the contamination amount of mycotoxin in cereals wherein one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.
    Type: Application
    Filed: June 8, 2012
    Publication date: September 20, 2012
    Applicants: Hokusan Co., Ltd, Mitsui Chemicals Agro, Inc.
    Inventors: Daisuke Awakura, Kiyoshi Kimura, Kazuyoshi Masuda
  • Patent number: 8188313
    Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: May 29, 2012
    Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer Research
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Publication number: 20120087975
    Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
    Type: Application
    Filed: October 21, 2011
    Publication date: April 12, 2012
    Applicant: MEDIGENE AG
    Inventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
  • Publication number: 20120065166
    Abstract: THE INVENTION RELATES TO compositions, compounds, proteins and methods of treatment therewith. Aspects of embodiments also relate to a method of treating a patient by delivering to the tissues of said patient or administering to said patient a therapeutically effective amount of one or more compounds. Aspects of embodiments also relate to a method of detecting the presence of bone disease by machine-assaying detectable serotonin. Aspects of embodiments also relate to methods of treating disease in subjects.
    Type: Application
    Filed: August 15, 2011
    Publication date: March 15, 2012
    Inventors: Virginia Espina, Lance Liotta, Antonella Chiechi, Alessandra Romano
  • Patent number: 8097752
    Abstract: Disclosed are novel ring containing phospholipids represented by the structural formula A-X—PO3—W and physiologically acceptable salts thereof and a process for the preparation of these compounds. The compounds can be used for the treatment of protozoal diseases and especially leishmaniasis.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: January 17, 2012
    Assignee: MAKScientific, LLC
    Inventors: Theodora Calogeropoulou, Maria Koufaki, Nikolaos Avlonitis, Alexandros Makriyannis
  • Patent number: 8039670
    Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or o
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: October 18, 2011
    Assignees: Ludwig Institute for Cancer Research, Chancellor Master and Scholars of the University of Oxford, The University of Birmingham
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Patent number: 7998945
    Abstract: The present invention relates to a method for the treatment and/or amelioration of atopic dermatitis, the method including the administration of a pharmaceutically active dose of a compound selected from miltefosine, edelfosine, perifosine and ilmofosine to a subject in need of such a treatment and/or amelioration.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: August 16, 2011
    Assignee: Jado Technologies GmbH
    Inventors: Tobias Braxmeier, Tim Friedrichson, Gary Jennings
  • Publication number: 20110135684
    Abstract: A method for treating and/or preventing certain ailments by administering to a person in need thereof L-?-lysophosphatidylcholine as an agent for activating the immune system of the person. Also, vaccine compositions that include L-?-lysophosphatidylcholine.
    Type: Application
    Filed: February 9, 2011
    Publication date: June 9, 2011
    Applicants: BIOMERIEUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Vincent Lotteau, Patrice Andre
  • Publication number: 20110118209
    Abstract: The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.
    Type: Application
    Filed: February 20, 2007
    Publication date: May 19, 2011
    Applicant: ZIOPHARM Oncology, Inc.
    Inventor: Robert Peter Gale
  • Publication number: 20100331274
    Abstract: This invention relates to certain chirally-correct mitoprotectant phosphorylated heterocyclic agents [formula (I)], which are useful for the treatment of dermatological disorders that include challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction; age spots; acne, loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness; skin depigmentation, and combinations thereof;
    Type: Application
    Filed: August 6, 2010
    Publication date: December 30, 2010
    Applicant: ISLAND KINETICS INC.
    Inventors: SHYAM K. GUPTA, LINDA WALKER
  • Publication number: 20100311698
    Abstract: The present invention is directed to aqueous based formulations of water-soluble prodrugs of propofol. The formulations comprise in aqueous medium an effective amount of the water-soluble prodrug of propofol in the absence of an antioxidant. The formulations are particularly useful as intravenous injections. The formulations preferably are buffered to a pH suitable for minimizing degradation of the prodrug during storage. The formulations can be prepared without the use of harmful co-solvents or surfactants and are stable at room temperature over extended periods of time.
    Type: Application
    Filed: September 20, 2007
    Publication date: December 9, 2010
    Applicant: EISAI CORPORATION OF NORTH AMERICA
    Inventors: Kanaiyalal R. Patel, Stephen Dordunoo, David Keller
  • Publication number: 20100311691
    Abstract: The present invention provides intranasal pharmaceutical compositions comprising an S-alkylisothiouronium derivative and methods of treating or alleviating upper respiratory and oral-pharyngeal congestions by pharmaceutical compositions comprising the S-alkylisothiouronium derivative.
    Type: Application
    Filed: November 6, 2008
    Publication date: December 9, 2010
    Inventors: Refael Barkan, Victor Ghicavii
  • Publication number: 20100285127
    Abstract: The present invention relates to taste masked compositions of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, in the form of a coated oral tablet having a desirable dissolution profile.
    Type: Application
    Filed: June 13, 2007
    Publication date: November 11, 2010
    Inventors: Refael Barkan, David Coffin-Beach, Victor Ghicavii
  • Patent number: 7713949
    Abstract: Compositions and methods for enhancing paracellular permeability at an absorption site in a subject are disclosed. The method includes: (a) administering an effective amount of a phospholipase C inhibitor to a subject at a time in which enhanced paracellular permeability is desired; and (b) enhancing paracellular permeability in the subject at the absorption site through the administering of the effective amount of the phospholipase C inhibitor. The disclosed compositions and methods provide enhanced absorption of a hydrophilic drug in a subject.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: May 11, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Dhiren R. Thakker, Peter D. Ward
  • Publication number: 20100062969
    Abstract: The present invention provides a method of correcting peptide or protein misfolding, which can be used to treat peptide and protein disorder in a mammalian subject. The method comprises administering to the mammalian subject, preferably a human subject, an effective amount of a composition comprising sterically stabilized simple micelles (SSM) of a hydrophilic polymer-conjugated lipid or sterically stabilized mixed micelles (SSMM) of a hydrophilic polymer-conjugated lipid and a water-insoluble lipid. The composition may further comprise a biologically active compound, such as but not limited to vasoactive intestinal peptide (VIP), associated with the SSM or SSMM.
    Type: Application
    Filed: April 6, 2007
    Publication date: March 11, 2010
    Inventors: Hayat Onyuksel, Israel Rubinstein
  • Publication number: 20100055201
    Abstract: The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.
    Type: Application
    Filed: October 26, 2007
    Publication date: March 4, 2010
    Inventor: Michael A. Zeligs
  • Patent number: 7655799
    Abstract: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N?,N?-tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: February 2, 2010
    Assignee: Telik, Inc.
    Inventors: Wenli Ma, Kevin T. Weber, Robert M. Yee
  • Publication number: 20090186854
    Abstract: The present invention relates to uses of S-alkylisothiouronium derivatives for treating inflammation. In particular, the present invention provides extended release pharmaceutical dosage forms of S-alkylisothiouronium derivatives and methods of use thereof for the treatment of various inflammatory diseases or conditions.
    Type: Application
    Filed: March 25, 2007
    Publication date: July 23, 2009
    Applicant: Meditor Pharmaceuticals Ltd.
    Inventors: Refael Barkan, Victor Ghicavii
  • Publication number: 20090104283
    Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.
    Type: Application
    Filed: December 1, 2008
    Publication date: April 23, 2009
    Applicant: N.V. NUTRICIA
    Inventors: Amanda Johanne KILIAAN, Robert Johan Joseph Hageman
  • Patent number: 7420000
    Abstract: Aminophosphonate and amino bisphosphonate compounds and methods for their preparation are provided. Also provided are pharmaceutical and agricultural compositions containing the compounds. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease, cardiovascular disease, bacterial infection, viral disease, abnormal cell proliferation, bone resorption disease, osteoporosis, or parasitic disease and in various agricultural methods, including, methods of eradicating weeds.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: September 2, 2008
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Publication number: 20080153782
    Abstract: Methods and compositions for the prevention and treatment of recent and old dermatitis, especially psoriasis, using lecithin or a lecithin-rich extract. According to one embodiment, phospholipids constituting the lecithin are esterified by Omega 3-type polyunsaturated fatty acids, in particular by docosahexaensic acid (DHA) and eicosapentaenoic acid (EPA) or by an alkyl glycerol. The lecithin can be of marine origin, extracted from a marine organisms such as fish, shrimp, krill, zooplankton, algae, and phytoplankton, which are advantageous in that their phospholipids, especially phosphatidylcholine, are naturally esterified by Omega 3 fatty acids, and essentially by DHA and EPA.
    Type: Application
    Filed: April 11, 2006
    Publication date: June 26, 2008
    Applicant: SC Dicophar
    Inventor: Paul Dupont
  • Patent number: 7288534
    Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: October 30, 2007
    Assignee: Center for Molecular Medicine and Immunology
    Inventors: David Modrak, David M. Goldenberg
  • Patent number: 7273604
    Abstract: Disclosed is a combination product for use in treating asthma and other respiratory conditions comprising a medicament comprising a surface active phospholipid composition in the form of a fine powder and an antiasthma drug. The product is arranged to be administered to the lungs by inhalation, for example, by the disclosed devices.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: September 25, 2007
    Assignee: Britannia Pharmaceuticals Limited
    Inventors: Brian Andrew Hills, Derek Alan Woodcock, John Nicholas Staniforth
  • Patent number: 7001896
    Abstract: The present invention provides a pharmaceutical composition for treating diabetes containing 4-diethoxyphosphinoylmethyl-N-(4-bromo-2-cyanophenyl)benzamide, particularly a pharmaceutical composition for treating diabetes that exhibits excellent effects for treating type II diabetes and the prevention of diabetic complications.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: February 21, 2006
    Assignees: Otsuka Pharmaceutical Factory, Inc.
    Inventors: Weidong Yin, Kazuhiko Tsutsumi
  • Patent number: 6794371
    Abstract: A method for preventing loss of bone mineral in mammals which method comprises administering to a mammal an amount of an aminoalkylenephosphonate which is effective to prevent or minimize loss of bone material density. The aminoalkylenephophonates of the present invention should have at least one R-N(Alk-PO3H2)2 group or at least two RRN-Alk-PO3H2 groups wherein R and R can be, same or different, aliphatic or cyclic moiety, and Alk is an alkylene group having from 1 to 4 carbon atoms.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: September 21, 2004
    Assignee: The Dow Chemical Company
    Inventor: R. Keith Frank
  • Patent number: 6784168
    Abstract: A synergistic biocide comprises a tris(hydroxymethyl)phosphine or a tetrakis (hydroxymethyl)phosphonium salt and at least one non-surfactant biopenetrant, such as a polymer or copolymer having a plurality of quaternary ammonium groups, a hydrotrope or a syntan, together optionally with a surfactant.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: August 31, 2004
    Assignee: Rhodia Consumer Specialties Limited
    Inventors: Christopher Raymond Jones, Robert Eric Talbot
  • Patent number: 6673378
    Abstract: An anti-catabolic dietary supplement, phosphatidylserine, and diet and exercise programs using phosphatidylserine for lean muscle development and optimized conditioning.
    Type: Grant
    Filed: November 1, 1995
    Date of Patent: January 6, 2004
    Inventor: Robert Fritz
  • Patent number: 6624152
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: September 23, 2003
    Assignee: Biogen, Inc.
    Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao
  • Patent number: 6593312
    Abstract: A compound of formula (I): wherein: represents an optionally substituted saturated carbon ring having from 4 to 8 ring members, R1 and R4, which may be identical or different, each represents hydrogen or acyl, R2 and R3, which may be identical or different, each represents hydrogen or alkyl, R5 and R6, which may be identical or different, each represents hydrogen or alkyl, or R5 and R6 together, with the nitrogen atom carrying them, form an optionally substituted nitrogen-containing heterocycle, stereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful for treatment of glucose intolerance or of disorders associated with hyperglycaemia.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: July 15, 2003
    Assignee: Les Laboratoires Servier
    Inventors: Michel Wierzbicki, Jean-Marie Fourquez, Nigel Levens, Bernadette Husson-Robert, Olivier Nosjean, Michelle Boulanger